|
1
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ramalingam SS, Owonikoko TK and Khuri FR:
Lung cancer: New biological insights and recent therapeutic
advances. CA Cancer J Clin. 61:91–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Roy M, Luo YH, Ye M and Liu J: Nonsmall
cell lung cancer therapy: Insight into multitargeted small-molecule
growth factor receptor inhibitors. BioMed Res Int. 2013:9647432013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lorigan P, Verweij J, Papai Z, Rodenhuis
S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick
A, Hogendoorn PC, et al; European Organisation for Research and
Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. Phase
III trial of two investigational schedules of ifosfamide compared
with standard-dose doxorubicin in advanced or metastatic soft
tissue sarcoma: A European Organisation for Research and Treatment
of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol.
25:3144–3150. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carrera S, Buque A, Azkona E, Aresti U,
Calvo B, Sancho A, Arruti M, Nuño M, Rubio I, de Lobera AR, et al:
Epidermal growth factor receptor tyrosine-kinase inhibitor
treatment resistance in non-small cell lung cancer: Biological
basis and therapeutic strategies. Clin Transl Oncol. 16:339–350.
2014. View Article : Google Scholar
|
|
7
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo ZS, Thorne SH and Bartlett DL:
Oncolytic virotherapy: Molecular targets in tumor-selective
replication and carrier cell-mediated delivery of oncolytic
viruses. Biochim Biophys Acta. 1785:217–231. 2008.PubMed/NCBI
|
|
11
|
Jiang G, Yang CS, Xu D, Sun C, Zheng JN,
Lei TC and Liu YQ: Potent antitumour activity of a novel
conditionally replicating adenovirus for melanoma via inhibition of
migration and invasion. Br J Cancer. 110:2496–2505. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Immonen A, Vapalahti M, Tyynelä K,
Hurskainen H, Sandmair A, Vanninen R, Langford G, Murray N and
Ylä-Herttuala S: AdvHSV-tk gene therapy with intravenous
ganciclovir improves survival in human malignant glioma: A
randomised, controlled study. Mol Ther. 10:967–972. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khuri FR, Nemunaitis J, Ganly I, Arseneau
J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C,
et al: A controlled trial of intratumoral ONYX-015, a
selectively-replicating adenovirus, in combination with cisplatin
and 5-fluorouracil in patients with recurrent head and neck cancer.
Nat Med. 6:879–885. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Doloff JC and Waxman DJ: Adenoviral
vectors for prodrug activation-based gene therapy for cancer.
Anticancer Agents Med Chem. 14:115–126. 2014. View Article : Google Scholar :
|
|
15
|
Kawashima T, Kagawa S, Kobayashi N,
Shirakiya Y, Umeoka T, Teraishi F, Taki M, Kyo S, Tanaka N and
Fujiwara T: Telomerase-specific replication-selective virotherapy
for human cancer. Clin Cancer Res. 10:285–292. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kasuya H, Takeda S, Shimoyama S, Shikano
T, Nomura N, Kanazumi N, Nomoto S, Sugimoto H and Nakao A:
Oncolytic virus therapy - foreword. Curr Cancer Drug Targets.
7:123–125. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang H, Wang H, Zhang J, Qian G, Niu B,
Fan X, Lu J, Hoffman AR, Hu JF and Ge S: Enhanced therapeutic
efficacy by simultaneously targeting two genetic defects in tumors.
Mol Ther. 17:57–64. 2009. View Article : Google Scholar
|
|
18
|
Yan FC, Wang QQ, Ruan YH, Ma LJ, Jia JT
and Jin KW: Establishment and biological characteristics of lung
cancer cell line XWLC-05. Ai Zheng. 26:21–25. 2007.(In Chinese).
PubMed/NCBI
|
|
19
|
Anders M, Christian C, McMahon M,
McCormick F and Korn WM: Inhibition of the Raf/MEK/ERK pathway
up-regulates expression of the coxsackievirus and adenovirus
receptor in cancer cells. Cancer Res. 63:2088–2095. 2003.PubMed/NCBI
|
|
20
|
Song X, Zhou Y, Jia R, Xu X, Wang H, Hu J,
Ge S and Fan X: Inhibition of retinoblastoma in vitro and in vivo
with conditionally replicating oncolytic adenovirus H101. Invest
Ophthalmol Vis Sci. 51:2626–2635. 2010. View Article : Google Scholar
|
|
21
|
Zhang C, Awasthi N, Schwarz MA, Hinz S and
Schwarz RE: Superior antitumor activity of nanoparticle
albumin-bound paclitaxel in experimental gastric cancer. PLoS One.
8:e580372013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu TC and Kirn D: Gene therapy progress
and prospects cancer: Oncolytic viruses. Gene Ther. 15:877–884.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bischoff JR, Kirn DH, Williams A, Heise C,
Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, et al:
An adenovirus mutant that replicates selectively in p53-deficient
human tumor cells. Science. 274:373–376. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Post DE, Khuri FR, Simons JW and Van Meir
EG: Replicative oncolytic adenoviruses in multimodal cancer
regimens. Hum Gene Ther. 14:933–946. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ranki T, Särkioja M, Hakkarainen T, von
Smitten K, Kanerva A and Hemminki A: Systemic efficacy of oncolytic
adenoviruses in imagable orthotopic models of hormone refractory
metastatic breast cancer. Int J Cancer. 121:165–174. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rajecki M, Kanerva A, Stenman UH, Tenhunen
M, Kangasniemi L, Särkioja M, Ala-Opas MY, Alfthan H, Sankila A,
Rintala E, et al: Treatment of prostate cancer with Ad5/3Delta24hCG
allows non-invasive detection of the magnitude and persistence of
virus replication in vivo. Mol Cancer Ther. 6:742–751. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nemunaitis J, Tong AW, Nemunaitis M,
Senzer N, Phadke AP, Bedell C, Adams N, Zhang YA, Maples PB, Chen
S, et al: A phase I study of telomerase-specific replication
competent oncolytic adenovirus (telomelysin) for various solid
tumors. Mol Ther. 18:429–434. 2010. View Article : Google Scholar :
|
|
28
|
Yu W and Fang H: Clinical trials with
oncolytic adenovirus in China. Curr Cancer Drug Targets. 7:141–148.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Freytag SO, Movsas B, Aref I, Stricker H,
Peabody J, Pegg J, Zhang Y, Barton KN, Brown SL, Lu M, et al: Phase
I trial of replication-competent adenovirus-mediated suicide gene
therapy combined with IMRT for prostate cancer. Mol Ther.
15:1016–1023. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yamamoto M, Davydova J, Wang M, Siegal GP,
Krasnykh V, Vickers SM and Curiel DT: Infectivity enhanced,
cyclooxy-genase-2 promoter-based conditionally replicative
adenovirus for pancreatic cancer. Gastroenterology. 125:1203–1218.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ganly I, Kirn D, Eckhardt G, Rodriguez GI,
Soutar DS, Otto R, Robertson AG, Park O, Gulley ML, Heise C, et al:
A phase I study of Onyx-015, an E1B attenuated adenovirus,
administered intratumorally to patients with recurrent head and
neck cancer. Clin Cancer Res. 6:798–806. 2000.PubMed/NCBI
|
|
32
|
Anders M, Rösch T, Küster K, Becker I,
Höfler H, Stein HJ, Meining A, Wiedenmann B and Sarbia M:
Expression and function of the coxsackie and adenovirus receptor in
Barrett’s esophagus and associated neoplasia. Cancer Gene Ther.
16:508–515. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brüning A, Stickeler E, Diederich D, Walz
L, Rohleder H, Friese K and Runnebaum IB: Coxsackie and adenovirus
receptor promotes adenocarcinoma cell survival and is
expressionally activated after transition from preneoplastic
precursor lesions to invasive adenocarcinomas. Clin Cancer Res.
11:4316–4320. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qin M, Escuadro B, Dohadwala M, Sharma S
and Batra RK: A novel role for the coxsackie adenovirus receptor in
mediating tumor formation by lung cancer cells. Cancer Res.
64:6377–6380. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fuxe J, Liu L, Malin S, Philipson L,
Collins VP and Pettersson RF: Expression of the coxsackie and
adenovirus receptor in human astrocytic tumors and xenografts. Int
J Cancer. 103:723–729. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yamamoto M and Curiel DT: Current issues
and future directions of oncolytic adenoviruses. Mol Ther.
18:243–250. 2010. View Article : Google Scholar :
|
|
37
|
Pesonen S, Kangasniemi L and Hemminki A:
Oncolytic adenoviruses for the treatment of human cancer: Focus on
translational and clinical data. Mol Pharm. 8:12–28. 2011.
View Article : Google Scholar
|
